Advanced search

Authors whose works are in public domain in at least one jurisdiction

List of works by Jyothis T George

1-50 of 53 results

View this query on the Wikidata Query Service
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

scientific article published on 01 January 2019
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

scientific article published on 4 December 2017
The kisspeptin-GnRH pathway in human reproductive health and disease

scientific article (publication date: 2014)
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

scientific article published on 13 September 2017
The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors

scientific article published on 24 August 2017
Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.

scientific article
Kisspeptin restores pulsatile LH secretion in patients with neurokinin B signaling deficiencies: physiological, pathophysiological and therapeutic implications

scientific article published on 24 February 2012
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

scientific article published on February 1, 2018
Lack of confidence among trainee doctors in the management of diabetes: the Trainees Own Perception of Delivery of Care (TOPDOC) Diabetes Study

scientific article
Hypothesis: kisspeptin mediates male hypogonadism in obesity and type 2 diabetes

scientific article published on 10 June 2010
Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism

scientific article published on 19 April 2013
Molecular clocks, type 2 diabetes and cardiovascular disease.

scientific article published on June 2008
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high

scientific article published on 14 March 2018
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

scientific article published on 01 January 2019
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

scientific article published on 25 October 2018
Kisspeptin antagonists: unraveling the role of kisspeptin in reproductive physiology

scientific article published on 18 September 2010
Clinical effectiveness of a brief educational intervention in Type 1 diabetes: results from the BITES (Brief Intervention in Type 1 diabetes, Education for Self-efficacy) trial

scientific article published on December 2008
Kisspeptin-10 stimulation of gonadotrophin secretion in women is modulated by sex steroid feedback

scientific article published on 05 September 2012
Training tomorrow's doctors in diabetes: self-reported confidence levels, practice and perceived training needs of post-graduate trainee doctors in the UK. A multi-centre survey

scientific article
Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control

article
Kisspeptin and the hypothalamic control of reproduction: lessons from the human

scientific article
How does obesity affect fertility in men - and what are the treatment options?

scientific article published on 16 September 2014
Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease

scientific article published in January 2018
Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality

scientific article published on 01 March 2019
Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline

scientific article published on 14 February 2019
Brief Intervention in Type 1 diabetes - Education for Self-efficacy (BITES): Protocol for a randomised control trial to assess biophysical and psychological effectiveness

scientific article
Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes

scientific article published on 15 March 2019
Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial

scientific article published on 31 January 2019
One-third of doctors completing specialist training in diabetes fail to secure a substantive consultant post: young Diabetologists' Forum Survey 2010.

scientific article published in June 2012
Differences in level of confidence in diabetes care between different groups of trainees: the TOPDOC diabetes study

scientific article
A survey in India of doctors' knowledge, attitudes and practice regarding telemedicine and e-health

scientific article published on 01 January 2007
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure

scientific article published on 05 June 2019
Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.

scientific article
Obstructive sleep apnoea; a rare cause of pseudophaeochromocytoma

scientific article published on 10 November 2011
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial

scientific article published on 01 December 2020
Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

scientific article published on 11 February 2019
Reversibility of fibrotic appearance of lungs with thyroxine replacement therapy in patients with severe hypothyroidism.

scientific article published in November 2009
Effect of a pocket-size tablet-dispensing device on glycaemic control in Type 2 diabetic patients

scientific article published in January 2007
Establishing pragmatic estimated glomerular filtration rate thresholds to guide metformin prescribing: careful assessment of risks and benefits is required

scientific article
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial

scientific article published on 29 September 2020
Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME

scientific article published on 25 June 2020
Consistent Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Irrespective of Diabetic Kidney Disease Categories - Insights from the EMPA-REG OUTCOME trial

scientific article published on 03 August 2020
THE INFLUENCE OF MICROVASCULAR DISEASE ON CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES: A POST HOC ANALYSIS OF EMPA-REG OUTCOME

scholarly article
THE ASSOCIATION BETWEEN URIC ACID LEVELS AND CARDIORENAL OUTCOMES AND DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME

scholarly article
Empagliflozin for Patients with Presumed Resistant Hypertension: a Post Hoc Analysis of the EMPA-REG OUTCOME Trial

scientific article published on 05 May 2020
Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME

scientific article published on 11 September 2020
Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial

scientific article published on 26 November 2020
Equality, transparency, fairness for all.

scientific article published in March 2007
SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA.

scientific article published on 30 April 2019
EMPAGLIFLOZIN IS ASSOCIATED WITH A LOWER RISK OF POST-ACUTE HEART FAILURE RE-HOSPITALIZATION AND MORTALITY: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL

scholarly article

Paulina is supported by:

About Paulina

Help